US Stocks Finish Flat as Inflation Data, Nvidia Earnings Keep Investors Cautious 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Gold Prices Rise Toward $4,650 Ahead of Warsh’s Jackson Hole Speech 
Bank of Korea Raises Rates to 3% as Inflation Stays Sticky 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Carney’s Trump Tariff Pushback Wins Canadian Support, but Economic Risks Mount 
Australia Inflation Beats Forecasts, Raising RBA Rate Hike Risk 
Oil Prices Slide on U.S.-Iran Ceasefire Reports, Hormuz Talks 
Japan Firms Ramp Up Yen Hedging as Currency Weakness Persists 
Asian Energy Stocks Slide as Iran-Oman Hormuz Talks Pressure Oil Prices 
Asian Chip Stocks Mixed After Nvidia Earnings Beat 
Add as a preferred source on Google
In a landmark move, Samsung Biologics and Pfizer Inc. have entered into a strategic $409 million contract manufacturing organization (CMO) agreement. This record-setting deal enlists Samsung Biologics to produce a range of biosimilar drugs originally developed by Pfizer, furthering global access to essential medicines.
The Korea Times reported that under the contract, Samsung Biologics will manufacture biosimilars made by Pfizer. These are biopharmaceutical medical products that are identical to the original product, which means the Korean biotech firm will replicate certain drugs originally made by Pfizer.
The biosimilars that Samsung Biologics will produce for the New York-based pharmaceutical and biotechnology firm include medical drugs for inflammation, tumors, and the immune system. The company built its fourth production plant in Incheon, South Korea, recently, so it is likely to be used for the fulfillment of the said CMO agreement.
“We are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe,” Samsung Biologics’ president and chief executive officer, John Rim, said in a press release. “This new meaningful partnership comes just as our Plant 4 is fully completed early this month as we had previously committed and are on the move for future expansion into our second campus in order to provide our clients with even more flexible and advanced manufacturing technology.”
Pfizer’s chief global supply officer, executive vice president, Mike Dermott, added, “Pfizer is excited to continue our strategic partnership with Samsung Biologics Ltd. that aims to enable greater access to medicines for more patients across the world. This commitment is a reflection of Pfizer’s trust in the Korean Pharmaceutical industry to address emerging health challenges.”
Meanwhile, the partnership between Samsung Biologics and Pfizer has set a new record for the latter and the entire history of biopharma in South Korea. This is because it is the largest single contract to ever be recorded in the country.
Photo by: Samsung Biologics Newsroom
